MedPath

Effect of Acupuncture in Treatment of Diabetes

Not Applicable
Recruiting
Conditions
Type 2 Diabetes Mellitus.
Type 2 diabetes mellitus
Registration Number
IRCT20180914041035N1
Lead Sponsor
Tehran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
80
Inclusion Criteria

Patients with diagnosis of type 2 diabetes mellitus according to American diabetes association diagnostic criteria, who are under treatment with metformin to control their blood glucose (500-1500 mg/day)
Signed the written informed consent
Fasting plasma glucose between 140-250 mg/dL
Aged 35-65 years

Exclusion Criteria

Cardiovascular diseases (history of heart failure, New York heart association function class III-IV, myocardial infarction, acute coronary syndromes, pacemaker implantation, coronary revascularization and stroke)
Renal impairment (urinary albumin excretion = 30 mg/day, estimated glomerular filtration rate < 60 mL/min/1.73 m2)
Hepatic impairment (abnormal serum aminotransferases, liver cirrhosis)
Cognitive impairment, inability of cooperation
Fasting plasma glucose = 250 mg/dL or hemoglobin A1C = 9
Pregnancy or breastfeeding
Diabetic patients that use other medications than metformin to control their blood glucose such as insulin
Evidence of lower limb infection, wound and ischemia (ecchymosis, bright skin, ABI<0.9)

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Fasting plasma glucose. Timepoint: Evaluating Fasting plasma glucose at baseline (before the treatment), and 1, 2, 4, 6 and 12 weeks after the initiation of treatment. Method of measurement: Laboratory kit.
Secondary Outcome Measures
NameTimeMethod
Hemoglobin A1c. Timepoint: Evaluating HbA1c at baseline (before the treatment) and 12 weeks after the initiation of treatment. Method of measurement: Laboratory kit.
© Copyright 2025. All Rights Reserved by MedPath